Abstract
Despite the fact that melanoma is a tumor of visual localization, mortality from skin melanoma remains one of the leading causes of mortality worldwide. Early metastasis of melanoma, even during the initial stages of the tumor process, indicates a high malignant potential of the tumor. Moreover, metastatic melanoma is resistant to current chemotherapy regimens, which is a significant problem today. Progression, resistance to drug therapy of skin melanoma is associated with a population of tumor stem cells, which are characterized by dysregulation of signaling pathways and aberrant phenotypes. The formation of tumor stem cells contributes to their microenvironment. Surface markers expressed by tumor stem cells include transporter proteins that mediate chemoresistance. The study of the microenvironment, the activity of the expressed antigenic determinants makes it possible to understand the processes of chemoresistance formation and to discover (develop) strategies for its overcoming. The article provides an analysis of the literature data on the significance of tumor stem cells in the development of drug resistance of melanoma.
Highlights
Несмотря на то, что меланома кожи относится к опухолям наружных локализаций, она является лидером по онкологической смертности во многих странах мира
Despite the fact that melanoma is a tumor of visual localization, mortality from skin melanoma remains one of the leading causes of mortality worldwide
Metastatic melanoma is resistant to current chemotherapy regimens, which is a significant problem today
Summary
Что меланома кожи относится к опухолям наружных локализаций, она является лидером по онкологической смертности во многих странах мира. РОЛЬ СТВОЛОВЫХ ОПУХОЛЕВЫХ КЛЕТОК В РАЗВИТИИ ЛЕКАРСТВЕННОЙ РЕЗИСТЕНТНОСТИ МЕЛАНОМЫ В статье приводится анализ современных данных литературы о значимости опухолевых стволовых клеток в развитии лекарственной резистентности меланомы. THE ROLE OF TUMOR STEM CELLS IN THE DEVELOPMENT OF DRUG RESISTANCE OF MELANOMA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.